Literature DB >> 10488054

Chronic exposure of smooth muscle cells to minimally oxidized LDL results in depressed inositol 1,4,5-trisphosphate receptor density and Ca(2+) transients.

H Massaeli1, J A Austria, G N Pierce.   

Abstract

Oxidized LDL (oxLDL) (0.1 mg/mL) increased [Ca(2+)](i) in vascular smooth muscle cells (VSMCs) within 5 to 10 seconds of incubation. This increase was mediated via an inositol 1,4,5-trisphosphate (IP(3))-dependent release of Ca(2+) from the sarcoplasmic reticulum. However, atherosclerosis is a gradual process in which VSMCs are more likely exposed to low concentrations of oxLDL over extended periods rather than acute exposures. It is very possible, therefore, that lower [oxLDL] and longer exposure times may induce a very different response with regard to regulation of [Ca(2+)](i). VSMCs were incubated with 4- to 100-fold lower [oxLDL] for up to 6 days. The conditions were not cytotoxic. Basal [Ca(2+)](i) was not altered. Surprisingly, however, after chronic exposure to oxLDL, a brief addition of oxLDL (0.1 mg/mL) or norepinephrine failed to elicit the expected rise in Ca(2+)(i). Because the acute effects of oxLDL on control cells were mediated through an IP(3)-dependent pathway, we investigated the integrity of the VSMC IP(3) receptors. Immunocytochemical analysis and Western blots revealed a depression in the density of IP(3) receptors after chronic exposure of VSMCs to oxLDL. These changes in IP(3) receptors have significance under atherosclerotic conditions as well. Immunocytochemical analysis revealed a decrease in IP(3) receptor density in the medial layer under atherosclerotic plaques in situ. Our data, therefore, demonstrate a striking difference between the acute and chronic effects of oxLDL on VSMC calcium. Whereas acute exposure to oxLDL stimulates [Ca(2+)](i), chronic exposure results in depressed Ca(2+) transients, apparently through a decrease in IP(3) receptor density. These changes have functional implications for the atherosclerotic vessel in vivo, and our data implicates oxLDL in this process.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10488054     DOI: 10.1161/01.res.85.6.515

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  6 in total

1.  Overexpression of SERCA2 Atpase in vascular smooth muscle cells treated with oxidized low density lipoprotein.

Authors:  H Massaeli; J A Austria; G N Pierce
Journal:  Mol Cell Biochem       Date:  2000-04       Impact factor: 3.396

Review 2.  Inositol trisphosphate receptors in smooth muscle cells.

Authors:  Damodaran Narayanan; Adebowale Adebiyi; Jonathan H Jaggar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-03-23       Impact factor: 4.733

Review 3.  Calcium Channels in Vascular Smooth Muscle.

Authors:  D Ghosh; A U Syed; M P Prada; M A Nystoriak; L F Santana; M Nieves-Cintrón; M F Navedo
Journal:  Adv Pharmacol       Date:  2016-10-14

4.  Importance of Altered Levels of SERCA, IP3R, and RyR in Vascular Smooth Muscle Cell.

Authors:  Jaijus Pallippadan Johny; Michael J Plank; Tim David
Journal:  Biophys J       Date:  2017-01-24       Impact factor: 4.033

5.  Epsin-mediated degradation of IP3R1 fuels atherosclerosis.

Authors:  Yunzhou Dong; Yang Lee; Kui Cui; Ming He; Beibei Wang; Sudarshan Bhattacharjee; Bo Zhu; Tadayuki Yago; Kun Zhang; Lin Deng; Kunfu Ouyang; Aiyun Wen; Douglas B Cowan; Kai Song; Lili Yu; Megan L Brophy; Xiaolei Liu; Jill Wylie-Sears; Hao Wu; Scott Wong; Guanglin Cui; Yusuke Kawashima; Hiroyuki Matsumoto; Yoshio Kodera; Richard J H Wojcikiewicz; Sanjay Srivastava; Joyce Bischoff; Da-Zhi Wang; Klaus Ley; Hong Chen
Journal:  Nat Commun       Date:  2020-08-07       Impact factor: 14.919

6.  The effect of intrauterine growth restriction on Ca2+ -activated force and contractile protein expression in the mesenteric artery of adult (6-month-old) male and female Wistar-Kyoto rats.

Authors:  Michael J Christie; Tania Romano; Robyn M Murphy; Giuseppe S Posterino
Journal:  Physiol Rep       Date:  2018-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.